Skip to Main Content

Author Details

Yaoqi Alan Wang
The University of Texas MD Anderson Cancer Center
1997
75
43
PMIDPaper TitleJournal TitlePublished Year
36585453Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer.Nat Cancer2023
37344599Histone demethylase KDM5D upregulation drives sex differences in colon cancer.Nature2023
37277603Glioblastoma heterogeneity at single cell resolution.Oncogene2023
35013211Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association.Nat Commun2022
35537038Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer.Cancer Discov2022
36163134USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer.Nat Commun2022
34298853Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer.Cancers (Basel)2021
33537102Abraxane-induced bone marrow CD11b[+] myeloid cell depletion in tumor-bearing mice is visualized by μPET-CT with [64]Cu-labeled anti-CD11b and prevented by anti-CSF-1.Theranostics2021
33887899Pro-angiogenic effect of exosomal microRNA-103a in mice with rheumatoid arthritis via the downregulation of hepatocyte nuclear factor 4 alpha and activation of the JAK/STAT3 signaling pathway.J Biol Regul Homeost Agents2021
35036927Telomerase Reverse Transcriptase Preserves Neuron Survival and Cognition in Alzheimer's Disease Models.Nat Aging2021
34531315USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer.Genes Dev2021
34475205AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase.Proc Natl Acad Sci U S A2021
32385075Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.Cancer Discov2020
32046984Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment.Cancer Discov2020
31919052Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor Microenvironment.Cancer Discov2020
32958778Telomere dysfunction activates YAP1 to drive tissue inflammation.Nat Commun2020
32392921Baicalin attenuates lipopolysaccharide-induced renal tubular epithelial cell injury by inhibiting the TXNIP/NLRP3 signalling pathway via increasing miR-223-3p expression.J Biol Regul Homeost Agents2020
32341020Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer.Cancer Discov2020
32337408Concurrent Injection of Unlabeled Antibodies Allows Positron Emission Tomography Imaging of Programmed Cell Death Ligand 1 Expression in an Orthotopic Pancreatic Tumor Model.ACS Omega2020
30307407Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target.J Clin Invest2019
30918400Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.Nature2019
30905761KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.Cancer Cell2019
29769196An <i>In Vivo</i> Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer.Cancer Res2018
30231203Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.ACS Nano2018
29352019Opposing roles of TGFβ and BMP signaling in prostate cancer development.Genes Dev2017
28166537Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.Nature2017
28099419Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer.Nature2017
28470201Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer.Nature2017
28289141Oncogenic <i>Kras</i> drives invasion and maintains metastases in colorectal cancer.Genes Dev2017
28321130Effective combinatorial immunotherapy for castration-resistant prostate cancer.Nature2017
28114741Loss of the transforming growth factor-β effector β2-Spectrin promotes genomic instability.Hepatology2017
28986382Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.Cancer Res2017
29073105PAF promotes stemness and radioresistance of glioma stem cells.Proc Natl Acad Sci U S A2017
26784546TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome.J Clin Invest2016
27723749SF2312 is a natural phosphonate inhibitor of enolase.Nat Chem Biol2016
27863244Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth.Cell2016
26861698Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.J Transl Med2016
26701088Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression.Cancer Discov2016
25808866Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.Cancer Res2015
26342024MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas.Cancer Prev Res (Phila)2015
26153864Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer.Nature2015
25965571Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.Cancer Cell2015
24954535Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.Cell2014
25119024Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.Nature2014
23918370From the Cover: Neutralization of terminal differentiation in gliomagenesis.Proc Natl Acad Sci U S A2013
22341440Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer.Cell2012
22751500STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA.Genes Dev2012
22895339Passenger deletions generate therapeutic vulnerabilities in cancer.Nature2012
22541435Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.Cell2012
22341455Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases.Cell2012
  • 1 - 50 of 75

Recommended Authors

Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 5
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 1
University of Toronto
Career Start Year 2005
Number of shared co-authors 3
International Centre for Genetic Engineering and Biotechnology
Career Start Year 2004
Number of shared co-authors 0
University of California los angeles
Career Start Year 2003
Number of shared co-authors 0
Seve Ballesteros Foundation Brain Tumor group
Career Start Year 2002
Number of shared co-authors 9
National Cancer Institute, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 6
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 0
University of Alabama at Birmingham
Career Start Year 1997
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 9
College of Medicine, The Catholic University of Korea
Career Start Year 1996
Number of shared co-authors 0
Department of Pediatrics Stanford University Stanford California USA.
Career Start Year 1993
Number of shared co-authors 4
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 1
University of Colorado Anschutz Medical Campus
Career Start Year 1991
Number of shared co-authors 0
The Institute of Cancer Research
Career Start Year 1990
Number of shared co-authors 1
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 2
Oncode Institute, Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 7
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 24
University of Toronto
Career Start Year 1988
Number of shared co-authors 3
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 6
Oregon Health and Science University
Career Start Year 1987
Number of shared co-authors 3
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 2
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 1981
Number of shared co-authors 1
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 6
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 6
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 38
National Cancer Institute
Career Start Year 1945
Number of shared co-authors 4

Collaborators

Co-authored papers 21
University of Texas MD Anderson Cancer Center
Co-authored papers 12
Co-authored papers 12
TESARO Inc.
Co-authored papers 7
Co-authored papers 7
Co-authored papers 7
Co-authored papers 7
Co-authored papers 6
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Dana-Farber Cancer Institute
Co-authored papers 6
Istituto Europeo di Oncologia IRCCS
Co-authored papers 6
The University of MD Anderson Cancer Center
Co-authored papers 6
Co-authored papers 5
Co-authored papers 4
Center for Global Health, School of Public Health, Nanjing Medical University
Co-authored papers 4
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Yale School of Medicine
Co-authored papers 3
Stanford University
Co-authored papers 3
NYU Grossman School of Medicine
Co-authored papers 3
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
University of Texas MD Anderson Cancer Center
Co-authored papers 3
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
MD Anderson Cancer Center
Co-authored papers 2
Massachusetts General Hospital
Co-authored papers 2
Co-authored papers 2